PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18268399-11 2008 CONCLUSION: Treatment with 90Y ibritumomab tiuxetan induced a clinically relevant CR in a patient with CD20-positive cHL. Chromium 82-84 keratin 20 Homo sapiens 103-107 11067958-2 2000 In (51)Cr release assays with whole blood as effector source, RAJI cells were effectively killed by a mouse/human chimeric IgG1 construct of CD20 Ab 1F5, whereas ARH-77 proved resistant to killing by this Ab. Chromium 7-9 keratin 20 Homo sapiens 141-145 9672771-6 1998 Complete remissions (CRs) appear to be more frequent and durable with radiolabeled anti-CD20 antibodies (33% to 85% CR rate) than with unmodified chimeric anti-CD20 antibodies (6% to 10% CR rate), although a randomized comparison has not yet been made. Chromium 21-23 keratin 20 Homo sapiens 88-92 9672771-6 1998 Complete remissions (CRs) appear to be more frequent and durable with radiolabeled anti-CD20 antibodies (33% to 85% CR rate) than with unmodified chimeric anti-CD20 antibodies (6% to 10% CR rate), although a randomized comparison has not yet been made. Chromium 116-118 keratin 20 Homo sapiens 88-92 29534755-7 2018 CD20+ B lymphocytes represented 14.9% in the dnIH group and 29.1% in the CR group. Chromium 73-75 keratin 20 Homo sapiens 0-4 16128896-13 2005 The anti-CD20 monoclonal antibody rituximab was given to two patients in conventional doses and a CR was seen in one patient. Chromium 98-100 keratin 20 Homo sapiens 9-13 24490292-6 2013 RESULT: Patients with CRS had higher infiltration of the B lymphocytes (CD20) and T lymphocyte subsets (CD4, CD88) than the patients of the control group (P < 0.05). Chromium 22-25 keratin 20 Homo sapiens 72-76